Rodolphe Barrangou is the Todd R. Klaenhammer Distinguished Professor in Probiotics Research in the Department of Food, Bioprocessing and Nutrition Sciences at North Carolina State University; Co-Founder and Chief Executive Officer of CRISPR Biotechnologies; Co-Founder and Chief Scientific Officer of Ancilia Biosciences; Co-Founder, President and Chief Scientific Officer of TreeCo; and Co-Founder and member of the Scientific Advisory Board of Intellia Therapeutics.
[1] In 2017, Barrangou was named[2] Editor-in-Chief of The CRISPR Journal, a peer-reviewed journal covering the field of genome editing and CRISPR research, which debuted in February 2018.
[4] He previously worked as an adjunct professor of Food Science at Pennsylvania State University, and R&D Director of Genomics at DuPont.
In 2007, Barrangou was the first author on a paper published in Science providing experimental proof for the immune function of CRISPR.
[5] He has worked with Jennifer Doudna on Cas9 guided RNA characterization.